Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

The effects of electronic cigarette vapour on the lung: direct comparison to tobacco smoke.

Reinikovaite V, Rodriguez IE, Karoor V, Rau A, Trinh BB, Deleyiannis FW, Taraseviciene-Stewart L.

Eur Respir J. 2018 Apr 4;51(4). pii: 1701661. doi: 10.1183/13993003.01661-2017. Print 2018 Apr. No abstract available.

PMID:
29449423
2.

Electronic Cigarettes Are as Toxic to Skin Flap Survival as Tobacco Cigarettes.

Rau AS, Reinikovaite V, Schmidt EP, Taraseviciene-Stewart L, Deleyiannis FW.

Ann Plast Surg. 2017 Jul;79(1):86-91. doi: 10.1097/SAP.0000000000000998.

PMID:
28252546
3.

Second hand smoke and COPD: lessons from animal studies.

Borchers MT, Kratzer A, Taraseviciene-Stewart L.

Front Physiol. 2014 Apr 10;5:144. doi: 10.3389/fphys.2014.00144. eCollection 2014. No abstract available.

4.

IL-32 promotes angiogenesis.

Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, Dinkel H, Palmer BE, Boisvert WA, Cool CD, Taraseviciene-Stewart L, Heinhuis B, Joosten LA, Dinarello CA, Voelkel NF, Nold MF.

J Immunol. 2014 Jan 15;192(2):589-602. doi: 10.4049/jimmunol.1202802. Epub 2013 Dec 11.

5.

Tobacco smoke induced COPD/emphysema in the animal model-are we all on the same page?

Leberl M, Kratzer A, Taraseviciene-Stewart L.

Front Physiol. 2013 May 15;4:91. doi: 10.3389/fphys.2013.00091. eCollection 2013.

6.

Endothelial cell adhesion molecule CD146: implications for its role in the pathogenesis of COPD.

Kratzer A, Chu HW, Salys J, Moumen Z, Leberl M, Bowler R, Cool C, Zamora M, Taraseviciene-Stewart L.

J Pathol. 2013 Aug;230(4):388-98. doi: 10.1002/path.4197.

PMID:
23649916
7.

Role of IL-18 in second-hand smoke-induced emphysema.

Kratzer A, Salys J, Nold-Petry C, Cool C, Zamora M, Bowler R, Koczulla AR, Janciauskiene S, Edwards MG, Dinarello CA, Taraseviciene-Stewart L.

Am J Respir Cell Mol Biol. 2013 Jun;48(6):725-32. doi: 10.1165/rcmb.2012-0173OC. Erratum in: Am J Respir Cell Mol Biol. 2014 Feb;50(2):470.

8.

New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis.

Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, Al Husseini A, Gomez-Arroyo JG, Voelkel NF, Bogaard HJ.

Pulm Circ. 2012 Oct;2(4):434-42. doi: 10.4103/2045-8932.105031.

9.

Usefulness of a mouse model of reversible pulmonary arterial hypertension: be cautious, choose carefully.

Gomez-Arroyo J, Voelkel NF, Bogaard HJ, Taraseviciene-Stewart L.

Am J Respir Crit Care Med. 2012 Jun 15;185(12):1326; author reply 1326-7. No abstract available.

PMID:
22707737
10.

Acrolein induces endoplasmic reticulum stress and causes airspace enlargement.

Kitaguchi Y, Taraseviciene-Stewart L, Hanaoka M, Natarajan R, Kraskauskas D, Voelkel NF.

PLoS One. 2012;7(5):e38038. doi: 10.1371/journal.pone.0038038. Epub 2012 May 31.

11.

Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease.

Taraseviciene-Stewart L, Voelkel NF.

Am J Respir Crit Care Med. 2012 May 1;185(9):1026; author reply 1026-7. No abstract available.

PMID:
22550215
12.

Interplay of macrophages and T cells in the lung vasculature.

Gerasimovskaya E, Kratzer A, Sidiakova A, Salys J, Zamora M, Taraseviciene-Stewart L.

Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L1014-22. doi: 10.1152/ajplung.00357.2011. Epub 2012 Mar 2.

13.

VEGF, poly(i:C), and innate immune response.

Taraseviciene-Stewart L, Voelkel NF.

Am J Respir Crit Care Med. 2012 Feb 15;185(4):462-3. No abstract available.

PMID:
22336685
14.

Vascular endothelial growth factor enhances macrophage clearance of apoptotic cells.

Kearns MT, Dalal S, Horstmann SA, Richens TR, Tanaka T, Doe JM, Boe DM, Voelkel NF, Taraseviciene-Stewart L, Janssen WJ, Lee CG, Elias JA, Bratton D, Tuder RM, Henson PM, Vandivier RW.

Am J Physiol Lung Cell Mol Physiol. 2012 Apr 1;302(7):L711-8. doi: 10.1152/ajplung.00116.2011. Epub 2012 Feb 3.

15.

A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D, Conrad DH, Nicolls MR, Voelkel NF.

Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L977-91. doi: 10.1152/ajplung.00362.2011. Epub 2012 Feb 3. Review.

16.

Imbalance of apoptosis and cell proliferation contributes to the development and persistence of emphysema.

Lee JH, Hanaoka M, Kitaguchi Y, Kraskauskas D, Shapiro L, Voelkel NF, Taraseviciene-Stewart L.

Lung. 2012 Feb;190(1):69-82. doi: 10.1007/s00408-011-9326-z. Epub 2011 Oct 21.

PMID:
22015802
17.

Immunomodulatory strategies prevent the development of autoimmune emphysema.

Hanaoka M, Nicolls MR, Fontenot AP, Kraskauskas D, Mack DG, Kratzer A, Salys J, Kraskauskiene V, Burns N, Voelkel NF, Taraseviciene-Stewart L.

Respir Res. 2010 Dec 16;11:179. doi: 10.1186/1465-9921-11-179.

18.

PI3K, Rho, and ROCK play a key role in hypoxia-induced ATP release and ATP-stimulated angiogenic responses in pulmonary artery vasa vasorum endothelial cells.

Woodward HN, Anwar A, Riddle S, Taraseviciene-Stewart L, Fragoso M, Stenmark KR, Gerasimovskaya EV.

Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L954-64. doi: 10.1152/ajplung.00038.2009. Epub 2009 Aug 14.

19.

Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone.

Homma N, Nagaoka T, Karoor V, Imamura M, Taraseviciene-Stewart L, Walker LA, Fagan KA, McMurtry IF, Oka M.

Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L71-8. doi: 10.1152/ajplung.90251.2008. Epub 2008 May 9.

20.
21.

Molecular pathogenesis of emphysema.

Taraseviciene-Stewart L, Voelkel NF.

J Clin Invest. 2008 Feb;118(2):394-402. doi: 10.1172/JCI31811. Review.

22.

Pulmonary arterial remodeling induced by a Th2 immune response.

Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, Grunig E, Grunig G.

J Exp Med. 2008 Feb 18;205(2):361-72. doi: 10.1084/jem.20071008. Epub 2008 Jan 28.

23.

VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells.

Sakao S, Taraseviciene-Stewart L, Cool CD, Tada Y, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, Tatsumi K, Kuriyama T, Voelkel NF.

FASEB J. 2007 Nov;21(13):3640-52. Epub 2007 Jun 13.

PMID:
17567571
24.

Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.

Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF.

Am J Respir Crit Care Med. 2007 Jun 15;175(12):1280-9. Epub 2007 Apr 5.

25.

Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF.

Circ Res. 2007 Mar 30;100(6):923-9. Epub 2007 Mar 1.

PMID:
17332430
26.

Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?

Taraseviciene-Stewart L, Douglas IS, Nana-Sinkam PS, Lee JD, Tuder RM, Nicolls MR, Voelkel NF.

Proc Am Thorac Soc. 2006 Nov;3(8):687-90. Review.

PMID:
17065374
27.

N-acetylcysteine treatment protects against VEGF-receptor blockade-related emphysema.

Demura Y, Taraseviciene-Stewart L, Scerbavicius R, Tuder RM, Voelkel NF.

COPD. 2004 Apr;1(1):25-32.

PMID:
16997736
28.

Mechanisms of autoimmune emphysema.

Taraseviciene-Stewart L, Burns N, Kraskauskas D, Nicolls MR, Tuder RM, Voelkel NF.

Proc Am Thorac Soc. 2006 Aug;3(6):486-7. No abstract available.

29.

Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.

Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF.

Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L668-76. Epub 2006 May 12.

30.

Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth.

Sakao S, Taraseviciene-Stewart L, Wood K, Cool CD, Voelkel NF.

Am J Physiol Lung Cell Mol Physiol. 2006 Sep;291(3):L362-8. Epub 2006 Apr 14.

31.

Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension.

Achcar RO, Demura Y, Rai PR, Taraseviciene-Stewart L, Kasper M, Voelkel NF, Cool CD.

Chest. 2006 Mar;129(3):696-705.

PMID:
16537870
32.

A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema.

Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Shapiro L, Zhang B, Song S, Hicklin D, Voelkel NF, Flotte T, Tuder RM.

Am J Respir Crit Care Med. 2006 Jun 1;173(11):1222-8. Epub 2006 Mar 2.

33.

Vascular endothelial growth factor receptor blockade by SU5416 combined with pulsatile shear stress causes apoptosis and subsequent proliferation of apoptosis-resistant endothelial cells.

Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF.

Chest. 2005 Dec;128(6 Suppl):610S-611S. No abstract available.

PMID:
16373861
34.

The expression of prostacyclin synthase is decreased in the small pulmonary arteries from patients with emphysema.

Lee JD, Taraseviciene-Stewart L, Keith R, Geraci MW, Voelkel NF.

Chest. 2005 Dec;128(6 Suppl):575S. No abstract available.

PMID:
16373836
35.

The protective role of T-lymphocytes in pulmonary vascular remodeling.

Taraseviciene-Stewart L, Scerbavicius DK, Burns N, Cool CD, Nicolls MR, Voelkel NF.

Chest. 2005 Dec;128(6 Suppl):571S-572S. No abstract available.

PMID:
16373829
36.

Autoimmunity and pulmonary hypertension: a perspective.

Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF.

Eur Respir J. 2005 Dec;26(6):1110-8. Review.

37.

Emphysema: an autoimmune vascular disease?

Voelkel N, Taraseviciene-Stewart L.

Proc Am Thorac Soc. 2005;2(1):23-5. Review.

PMID:
16113465
38.

Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells.

Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF.

FASEB J. 2005 Jul;19(9):1178-80. Epub 2005 May 16.

PMID:
15897232
39.

Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.

Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA Jr, Taraseviciene-Stewart L.

Peptides. 2005 Aug;26(8):1288-91.

PMID:
15878795
40.

Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy.

Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, Kasper M, Voelkel NF.

Peptides. 2005 Aug;26(8):1292-300.

PMID:
15878794
41.

An animal model of autoimmune emphysema.

Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Moore M, Sullivan A, Nicolls MR, Fontenot AP, Tuder RM, Voelkel NF.

Am J Respir Crit Care Med. 2005 Apr 1;171(7):734-42. Epub 2004 Nov 24.

PMID:
15563631
42.

Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth.

Golpon HA, Fadok VA, Taraseviciene-Stewart L, Scerbavicius R, Sauer C, Welte T, Henson PM, Voelkel NF.

FASEB J. 2004 Nov;18(14):1716-8. Epub 2004 Sep 2.

PMID:
15345697
43.

Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade.

Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y, Salvemini D, Voelkel NF, Flores SC.

Am J Respir Cell Mol Biol. 2003 Jul;29(1):88-97. Epub 2003 Jan 31.

PMID:
12600822
44.

Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats.

Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF.

Am J Respir Crit Care Med. 2003 Jun 1;167(11):1516-21. Epub 2003 Jan 9.

PMID:
12522028
45.

Bradykinin antagonists as new drugs for prostate cancer.

Stewart JM, Chan DC, Simkeviciene V, Bunn PA Jr, Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L.

Int Immunopharmacol. 2002 Dec;2(13-14):1781-6.

PMID:
12489792
46.

A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.

Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM.

Can J Physiol Pharmacol. 2002 Apr;80(4):269-74.

PMID:
12025960
47.

Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.

Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF.

J Pathol. 2001 Oct;195(3):367-74.

PMID:
11673836
48.

The pathobiology of pulmonary hypertension. Endothelium.

Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF.

Clin Chest Med. 2001 Sep;22(3):405-18. Review.

PMID:
11590837
49.

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.

Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM.

FASEB J. 2001 Feb;15(2):427-38.

PMID:
11156958
50.

Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.

Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF.

J Clin Invest. 2000 Dec;106(11):1311-9.

Supplemental Content

Loading ...
Support Center